It appears likely that the relative importance of the different TP53/TRP53-activated cellular responses for tumour suppression may vary between cell types undergoing neoplastic transformation and with respect to the nature of the oncogenic lesions that drive tumorigenesis (Kastenhuber and Lowe, 2017; Thomas et al, 2022). The gene discussed is TP53; the disease is neoplasm.